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Abstract: 
Background: 
Apathy is a common feature of Huntington’s disease (HD), even from early disease. However, 
patients are believed to lack insight into their own apathy and therefore clinicians and/or 
companions are relied upon to estimate the extent of a patient’s apathy. In addition, the evolution 
of apathy over time in HD has not been unequivocally established. 
 
Objectives: 
The purpose of this study was to determine whether HD patient’s self-rated apathy scores were 
consistent with the scores given by companions who were also asked to rate the patients apathy. 
Furthermore, the clinical correlates of apathy and its stability over time were examined for both 
self-rated and companion-rated scores.  
 
Methods: 
Apathy was measured in a large cross-sectional population of HD patients ranging from early to 
late stage disease (n = 106) using the Apathy Evaluation Scale; a subgroup of whom were 
followed longitudinally (n = 62) on average 18.7 (1.2 SD) months later. Comparisons were made 
between self-rated and companion-rated apathy and the relationship between apathy and motor, 
cognitive and functional performance was explored. 
 
 
 
Results: 
Analysis of the cross-sectional data revealed that self-rated and companion-rated apathy were 
highly correlated, establishing the validity of using self-rated instead of, or in combination with, 
companion-rated assessments of apathy in future studies. Both self-rated and companion-rated 
scores had a relationship with motor and functional impairment, but had a complex relationship 
with cognition. The results of the longitudinal comparison revealed that apathy did not change 
over time in this cohort.  
 
Conclusions: 
Apathy can be equally well assessed by either patients or companions and does not change 
significantly over an 18 month period. These findings have implications in the design of studies 
looking at treating this important aspect of HD.  
 
  
Introduction 
Huntington’s disease (HD) is an incurable, inherited, progressive neurodegenerative disorder that 
is characterised by a triad of motor, cognitive and psychiatric problems [1]. The psychiatric 
disturbances experienced in HD are the least well understood of the three cardinal features of the 
disease in terms of both their pathology and etiology. Depression, irritability, anxiety and apathy 
are commonly reported by HD patients and their companions [2], with both gene carriers and 
manifest patients showing an increased risk of suicide [3, 4]. However, in general the incidence 
of psychiatric disturbances in HD is both variable and transient and in most cases does not 
closely map to disease progression [5]. 
 
Prior to the 1990s psychiatric changes in HD were grouped together with problems such as 
apathy, irritability and social withdrawal collectively termed “personality change”. Historically, 
it has not always been possible to distinguish apathy from other psychiatric syndromes such as 
depression. This is because apathy is a symptom in many mental disorders but is less frequently 
considered as a syndrome itself [6]. There is now particular interest in defining the etiology and 
clinical impact of individual syndromes such as depression, irritability and more recently apathy 
in HD. This is because currently, there are no effective treatments to ameliorate the symptoms of 
apathy therefore treating apathy as a distinct syndrome may help identify novel targets for future 
therapeutic trials. It should be acknowledged however, that the syndromal approach to studying 
the behavioural disturbances in HD may actually hinder research by artificially simplifying what 
is a complex element of the clinical phenotype of HD with many concurrent, intertwined 
neuropsychiatric elements.      
  
Apathy can be a particularly problematic feature of HD; the behavior is often poorly understood 
by those around the patient with apathetic behavior commonly misinterpreted as awkwardness or 
stubbornness, leading to hostility and putting a strain on social relationships. The prevalence in 
HD is believed to be high, with between 50% - 99% of patients experiencing apathetic symptoms 
at some point during their disease [7, 8]. It has been shown to be dissociable from depression [9], 
to be present from the early stages of the disease [10] and unlike other neuropsychiatric features, 
to become more severe as the disease advances [11-14]. Apathy correlates with both cognitive 
performance [13, 15] and functional decline [16-18] and is predictive of future functional 
capabilities in early HD, although this relationship is not necessarily causal [10].  
 
Measuring apathy accurately in HD can be problematic. Historically, clinician administered 
behavioural inventories such as the UHDRS Behavioural Scale [19] or the Problem Behaviour 
Assessment (PBA)  [12] have been used in HD. These semi-structured interviews, conducted 
with the patient and/or companion, measure apathy in conjunction with 10 other behavioural 
problems, and record the frequency and severity of symptoms using a 0 to 4 (for the UHDRS 
Behavioural Scale) or 5 (PBA) likert scale with 0 indicating NO apathy. 
 
Such scales require the administering clinician to be suitably trained and appropriately skilled 
which limits the utility of the scales in many settings. Furthermore, while both scales provide 
data on a range of behavioural problems in HD, the depth of information about any one 
individual condition is limited. Therefore, detecting subtle but clinically meaningful changes 
using either the UHDRS Behavioural Scale or the PBA can be difficult, increasing the chances of 
a type II error.  
 
The Apathy Scale (AS) [20] is the only self-rated measure dedicated exclusively to apathy that 
has been used in HD to date. Other self-rated scales such as the Frontal Systems Behaviour Scale 
(FrSBe) have been used which contain a separate subscale on apathy [21] but cover the issue in 
less detail. The AS requires the patient’s companion to rate the extent of apathetic symptoms 
experienced by the patient. This is due to the assumed lack of insight of HD patients into their 
psychiatric problems. However, there is little evidence that HD patients do in fact lack insight 
into their apathy, although previous research has shown that they may lack insight into their 
cognitive abilities [22, 23] and motor signs of disease [24]. One previous study has reported poor 
agreement between patient-rated and companion-rated apathy in patients with low cognitive 
scores but beyond this the agreement is considered as “fair” or better [25]. This reliance on the 
presence of a companion can be problematic when designing a clinical trial as it restricts the 
cohort of eligible patients to those who have a reliable companion willing to accompany them for 
study visits. What is more, it creates a potential recruitment bias as patients with a good support 
network tend to fare better psychiatrically than those without. 
 
The current study therefore sought to identify whether patients and their companions evaluated 
apathy in the same way. To do this apathy was measured using the Apathy Evaluation Scale 
(AES) [26] which is a well validated likert style assessment scale [26-29] that exists in parallel 
versions for the participant and companion allowing for direct comparison between the two 
groups. Furthermore, we looked at the relationship between both self-rated and companion-rated 
apathy with disease stage, depression and measures of cognition. Finally, patients were re-
evaluated after approximately 18 months to evaluate the stability of apathy measures over time 
and to identify whether this changed depending upon who provided the rating.           
 
 
Materials and methods 
Participants: 
105 HD patients at baseline and 72 patients at follow up (on average 18.7 months later) ranging 
from pre-manifest HD gene carriers to patients with advanced disease were recruited into this 
study. Participants were identified through the HD service clinic at the John Van Geest Centre 
for Brain Repair, UK and had previously received genetic confirmation of their HD gene status 
with a CAG repeat length of greater than 38 repeats. Participants without a companion also were 
included in the study.  
 
Participants were tested as part of their routine clinic appointment therefore ethical approval was 
not obtained prior to testing but permission was granted to analysis of the data by Addenbrooke’s 
Hospital Research & Development (R&D) department.  
 
Procedure: 
Data was collected at baseline and follow-up in one of two ways: 
1. During clinic: Patients due for their annual neuropsychological assessment completed the 
AES-Participant version (AES-P) at the end of cognitive battery. If accompanied by a 
companion, the companion was asked to complete the AES-Companion version (AES-C). 
2. At home: Those participants who attended clinic outside of their annual appointment due 
to clinical need were given the AES-P and AES-C to take home. A pre-paid envelope in 
which to return the completed forms was provided. Where participants had completed the 
cognitive battery within 6 months of the AES this clinic information was associated with 
the AES assessment. Data was recorded as missing if the clinic assessment was greater 
than 6 months from the date of the AES. 
 
 
 
 
Assessments: 
Apathy 
Apathy was assessed using the self-report version of the Apathy Evaluation Scale (AES-P), and 
the parallel companion version of the same instrument (AES-C)[26]. The AES [26] is an 18 item 
rating Likert scale where responders are asked to rate the extent to which they agree with a 
specific statement with responses consisting of not at all, slightly, somewhat, and very. The 
internal consistency of both the self-report and companion versions of the AES is good with 
Cronbach alpha scores of 0.94 and 0.86 respectively, and test-retest reliability of 0.94 and 0.76 
respectively [26].    
HD Clinical features 
A comprehensive assessment of the motor signs and functional symptoms of HD was completed 
by an experienced neurologist using the widely validated, standardized, clinical rating scale the 
Unified Huntington’s Disease Rating Scale (UHDRS) [19]. Only the total motor score, 
functional assessment (FA) and total functional capacity (TFC) sections of the UHDRS were 
used. Manifest patients were staged according to previously published criteria based on the Total 
Functional Capacity (TFC) score: scores of between 11 and 13 were classified as early disease, 
between 7 and 10 as moderate disease and scores of 6 and less as late disease [30].  
    
Cognition 
For patients who participated during their routine clinic appointment the neuropsychological data 
was collected at the same time. For those who participated via post the neuropsychological 
assessment was completed within one year of their completion of the AES.  
 
Global cognitive function was assessed with the Mini Mental State Exam (MMSE) [31]. Verbal 
fluency capabilities were evaluated by tests of phonemic (letter) and semantic (category) fluency. 
Phonemic fluency is thought to be sensitive to frontostriatal deficits [32, 33] and category 
fluency is sensitive to more temporal lobe deficits [34-36]. 
 Memory was measured using the CANTAB computerized pattern recognition memory (PRM) 
and spatial recognition memory (SRM) tasks [37]. PRM measures the ability to recognize visual 
patterns following a short delay as indexed by the percent of patterns correctly recognized from 
novel distractors and is thought to be sensitive to temporal lobe and hippocampal damage [38]. 
SRM measures the ability to recognize spatial orientation of visual stimuli following a short 
delay, as indexed by the percent of placements recognized correctly from distractors with novel 
placements and is thought to be sensitive to frontal lobe abnormalities [38, 39]. 
Depression 
Depression was assessed using the Beck Depression Inventory (BDI), a 21 item self-report scale 
[40] used widely worldwide [41] as it provides a robust measure of depression without requiring 
the presence of a clinician.  
 
Data Analysis 
Shapiro-Wilk tests revealed that the AES data was not normally distributed therefore non-
parametric analyses were used. Between-group differences were calculated using a Kruskal-
Wallis test with AES scores as the dependent variable and the value of interest as the 
independent variable. Spearman’s Rho correlations were used to measure the association 
between variables and change over time was evaluated using the Mann-Whitney U test. Where 
possible data was categorized according to published guidelines (BDI [40] and AES [27] and 
between group comparisons were made. Finally, principal component analysis was used to 
identify the items of the AES which accounted for the greatest variance in both the self-rated and 
companion rated scores.  
 
All analysis was performed using Predictive Analytic SoftWare (PASW) Statistics, version 21. 
 
Results: 
Demographic and clinical information 
Baseline participant demographic and clinical data is summarised in Table 1. Patients with and 
without a companion did not differ from one another in the degree of self-rated apathy they 
reported (p=0.598) nor in their UHDRS motor score (p=0.257), age (p=0.853) or disease 
duration (p=0.14), although patients without a companion were significantly less depressed (with 
companion, mean BDI: 10.99, S.D: 9.8, without companion, mean BDI: 6.74, S.D: 6.9; p<0.05)). 
 
Over the 18.7 months (S.D. 1.2 months) follow up, 37.9% of patients were lost to follow-up (see 
figure 5) which also meant that the population of companion raters was reduced by 57.5%. Of 
those patients not followed up 8 (7.6%) withdrew because of advancing disease, 4 (3.8%) 
patients died and the remaining 25 (25.6%) did not return to clinic or respond to attempts to 
contact them. The baseline characteristics of patients who completed the AES at both time points 
are shown in table 2. 
 
 
  
 
Table 1: Baseline demographic characteristics and clinical data  for all participants completing the Apathy Evaluation Form 
 All patients Patients with companions 
 Pre-HD Early Moderate Late Pre-HD Early Moderate Late 
N 16 24 29 35 15 15 17 25 
Gender (m:f) 8:8 21:7 10:19 16:19 4:11 4:11 7:10 10:15 
Age 46.8 (15.1) 53.8 (13.6) 54.2 (7.3) 56.7 (12.3)* 46.7 (16.6) 57.7 (13.9) 51.5 (7.7) 58.0 (13.4) 
CAG 42.5 (2.8) 42.9 (3.3) 42.4 (1.7) 43.1 (3.1) 42.4 (2.9) 42.6 (3.6) 42.8 (1.6) 43.7 (4.4) 
Disease duration -9.5 (7.9) 6.7 (6.5)* 12.0 (5.5)* 11.1 (4.9)* -9.9 (8.0) 6.1 (7.1)* 11.4 (5.2)* 11.6 (5.1)* 
UHDRS 1.7 (1.9) 16.0 (7.3)* 26.4 (13.1)* 42.5 (12.0)* 1.5 (1.7) 15.1 (8.0)* 26.6 (14.3)* 42.6 (12.6)* 
FA 24.6 (1.1) 23.8 (1.2) 20.0 (3.2)* 13.9 (7.1)* 24.5 (1.1) 23.8 (1.1) 19.8 (3.8)* 13.6 (7.7) 
MMSE 28.4 (2.6) 27.0 (2.2) 26.5 (3.0) 22.4 (4.4)* 28.2 (2.7) 26.8 (2.5) 26.3 (3.1) 21.7 (4.5)* 
BDI 6.5 (6.1) 4.6 (4.9) 13.8 (10.6) 11.7 (9.6) 6.8 (6.2) 5.4 (5.1) 16.3 (11.2)* 13.2 (10.2) 
Phonemic fluency 37.1 (13.8) 28.5 (12.8) 26.8 (13.2) 14.0 (7.5)* 37.2 (14.6) 29.2 (15.6) 27.6 (12.9) 11.3 (6.6)* 
Semantic fluency 20.0 (5.4) 14.7 (4.4) 13.4 (5.4)* 8.3 (3.5)* 20.7 (5.6) 15.5 (4.4) 12.3 (5.8)* 7.5 (3.8)* 
CANTAB PRM 18.2 (5.1) 16.8 (2.7) 16.7 (3.6) 14.2 (4.2) 17.6 (5.5) 16.5 (2.9) 16.7 (3.8) 15.4 (2.2) 
CANTAB SRM 13.4 (4.4) 13.5 (2.8) 13.4 (2.7) 12.0 (3.4) 13.4 (4.4) 13.5 (2.7) 12.9 (3.1) 12.9 (2.5) 
*Significant difference compared to pre-HD (p<0.05) 
Abbreviations: BDI: Beck Depression Inventory, CAG: cytonsine-adenine-guanine, CANTAB PRM: Cambridge 
Neuropsychological Test Automated Battery Pattern Recognition Memory, CANTAB SRM: Cambridge Neuropsychological 
Test Automated Battery Spatial Recognition Memory, MMSE: Mini Mental State Exam, pre-HD: pre-manifest HD gene 
carriers, UHDRS: Unified Huntington’s Disease Rating Scale, FA: UHDRS Functional Assessment 
Inter-rater reliability 
Self-rated and companion rated AES scores correlated significantly with one another (r
2
 = 0.76, 
p<0.001) indicating a high degree of rater agreement between these two measures and 
demonstrating evidence of high construct validity supporting the use of the self-rated AES in 
HD. Furthermore, a related-samples Wilcoxon Signed Rank Test showed that there was no 
statistical difference between individual participants self-rated apathy and their companions 
rating of the patients apathy (Z = -1.02, p = 0.307,ns). 
 
The prevalence of apathy in HD was estimated using published cut-off scores [27]  originally 
generated for use with patients following traumatic brain injury (TBI) [42] (scores of >41 for the 
patient rated AES scale and >39 for the companion rated AES scale are considered to be 
indicative of apathy). Based on this, 26.9% (29/108) of HD patients were classified as apathetic 
according to patient rated AES scores whereas, 50.6% (40/79) of patients met the criteria for 
apathy based upon the companion rated AES scores. When the patient rate cut-off criteria were 
applied to the companion rated scores the prevalence of apathy based upon the companion AES 
scores fell to 37.9% (30/79). Given that there is no statistical difference between a patient’s 
ratings of their own apathy and their companion’s rating of the patient’s apathy these results 
suggest that the published criteria need to be adapted for use in HD.  
 
Relationship to disease stage: 
There was a significant main effect of disease stage for both self-rated (X
2
(3) = 11.98, p < 0.01) 
and companion rated apathy (X
2
(3) = 28.87, p<0.001). Post-hoc analysis revealed that, for self-
rated apathy, both pre-manifest HD gene carriers and early HD patients had significantly less 
self-rated apathy than those with late disease (p < 0.05); moderate and late HD groups did not 
differ significantly from one another (figure 1). For companion-rated apathy, pre-manifest HD 
gene carriers and early stage patients differed significantly from moderate stage patients (p < 
0.05) as well as those with late disease (p < 0.005).  
 
 
Figure 1 Mean response on the Apathy Evaluation Scale for both participants and 
companions stratified by disease stage. * indicates a significant difference at 
the p=0.05 level. Bars represent means 95% confidence intervals of the 
mean 
 
 
 
 
 
 
 
 
 
 
 
 
By definition, apathy is associated with reduced levels of daily functioning therefore to ensure 
that this association was not a circular construct (e.g. great levels of apathy led to a reduced total 
* * 
* * 
functional capacity score and therefore a higher disease stage) AES scores were correlated with 
UHDRS scores. Total UHDRS scores correlated with self-rated apathy (r
2
 = 0.21, p<0.05) and 
companion-rated apathy scores (r
2
 = 0.56, p<0.001) (Figure 2).  
 
 
Figure 2. Mean response on the Apathy Evaluation Scale correlated with total 
motor performance for (A) participant responses and (B) companion responses.      
represents line of best fit.         
     
A            B 
 
 
 
 
 
 
 
 
 
In addition, there was a negative correlation between rater agreement and UHDRS scores (r
2
 = -
0.42, p <0.001) indicating that this relationship changes with advancing disease. When presented 
graphically it becomes apparent that in pre-manifest and early disease patients tend to rate 
themselves as more apathetic than their companion does however, by late stage disease this 
relationship has switched so that it is companions who are rating the apathy more severely than 
the patients (figure 3).   
 
 
  
 
Figure 3: Difference between patient’s self-rated apathy and companions ratings of the 
patients apathy (calculated as AES-P – AES-C), correlated with total motor performance. 
represents line of best fit.         
 
 
 
 
 
 
 
 
Relationship to depression 
Both self-rated and companion rated apathy correlated with depression (r
2
 = 0.50, p < 0.001; r
2
 = 
0.48, p < 0.01 respectively). A main effect of depression was found for both self-rated (X
2
(3) = 
21.87, p < 0.001) and companion rated scores (X
2
(3) = 7.79, p = 0.05) when patients were 
grouped according to symptom severity according to published criteria [40] (no depression [BDI 
<10], patient n = 55, companion n = 38; mild depression [BDI 10-15], patient n = 21, companion 
n = 14; moderate depression [BDI 16-30], patient n = 15, companion n = 12; severe depression 
[BDI >30], patient n = 4, companion n = 4). Post-hoc analysis revealed that patients with no 
depression rated themselves as significantly less apathetic than those with either mild (p<0.01) or 
moderate (p<0.001) depression but not different from those with severe depression (although our 
sample size was only 4). Patients with mild, moderate or severe depression did not differ 
significantly from one another in terms of their degree of apathy. For companion ratings the total 
AES score was significantly different when comparing patients classified as having no 
depression compared to those with moderate depression only (p<0.05), (figure 4). 
 
 
Figure 4. Mean response on the Apathy Evaluation Scale for both participants 
and companions stratified by depression score . * indicates a significant 
difference compared to both moderate and late groups at the p=0.05 level. 
Bars represent means 95% confidence intervals of the mean  
 
 
 
 
* * 
Relationship to cognitive performance: 
Self-rated apathy scores correlated with performance on the MMSE (r
2
 = -0.24, p < 0.05) and 
CANTAB SRM (r
2
 = -0.35, p<0.01), whereas performance on the MMSE (r
2 
= -0.51, p < 0.001) 
phonemic (r
2
 = -0.55, p <0.001), semantic fluency (r
2 
= -0.51, p < 0.001) and CANTAB SRM (r
2
 
= -0.46, p< 0.001) tasks correlated with companion-rated apathy.  
 
Inter-rater reliability between the AES-P and AES-C did not correlate with the MMSE (r
2
 = 0.19, 
p < 0.20 ns) but did correlate with phonemic fluency (r
2
 = -0.37, p <0.01), semantic fluency (r
2
 = 
-0.32, p <0.038) and CANTAB SRM (r
2
 = -0.34, p <0.044). This suggests that the extent of rater 
agreement did not relate to global cognitive performance but may have a relationship with the 
extent of executive dysfunction in HD. However, similar to the UHDRS, the correlation between 
cognitive performance and rater agreement represents a switch from higher participant ratings in 
pre-manifest and early disease to higher companion ratings by late stage disease. 
 
Medications effects 
The impact of dopamine blocking/depleting drugs commonly used to treat HD (sulpiride, 
amisulpiride, olanzapine, tetrabenazine or haloperidol) on AES scores was examined. As the 
likelihood of being prescribed antidopaminergic medication increases with advancing disease 
only the late-HD group were evaluated (due to insufficient numbers of patients taking 
antidopaminergic medication in the mild and moderate HD groups). Patients prescribed 
antidopaminergic medication had higher self-reported apathy (U = 97.0, p = 0.043) and 
companion rated apathy (U = 25.0, p = 0.013).  
 Change over time 
The prevalence of apathy at follow up was estimated as 30.9% (21/68) and 56.9% (29/51) for 
self-rated and companion-rated apathy respectively. Of the 29 patients classified as apathetic 
according to the self-ratings at baseline, 13 remained apathetic, 9 were no longer classified as 
apathetic at follow up and 7 were lost to follow up. Of the 79 patients classified as non-apathetic 
according to patient ratings at baseline, 38 remained non-apathetic at follow up, 34 were lost to 
follow up and 7 Patients who were not classified as apathetic at baseline became apathetic by 
follow up. 
 
Of the 40 patients classified as apathetic according to the companion ratings at baseline, 18 
remained apathetic, 1 was no longer classified as apathetic at follow up and 21 were lost to 
follow up. Of the 39 patients classified as non-apathetic at baseline, 14 remained non-apathetic, 3 
became apathetic and 22 were lost to follow up (figure 5). 
 
Total AES scores at baseline and follow-up correlated significantly for both the self-rated (n = 
67, r
2
 = 0.71, p < 0.001) and companion-rated responses (n = 51, r
2
 = 0.57, p < 0.05). 
Furthermore, a Wilcoxon signed-rank tests found no significant difference in self-rated AES 
scores at baseline (mean = 35.6, S.D. = 12.72) and follow-up (mean = 36.2, S.D. =12.38); (Z =    
-0.141, p = 0.21). Although, companion-rated AES scores were significantly lower at baseline 
(mean = 37.5, S.D. = 13.98) than at follow up (mean = 40.5, S.D. = 14.81); (Z = -1.99, p < 0.05). 
 
Further analysis found that patients who remained consistently apathetic had significantly lower 
baseline FA (apathetic 15.5 (5.9 S.D.) vs non-apathetic 21.5 (4.6 S.D.), (U = 206.5, p<0.001)), 
higher BDI scores (apathetic 16.6 (9.8 S.D.) vs non-apathetic 5.8 (6.1 S.D.), (U = 157.5, 
p<0.001)) and more advanced disease stage (apathetic 2.5 (0.8 S.D.) vs non-apathetic 1.5 (0.8 
S.D.), (U = 237.0, p<0.001). They were also more likely to be taking anti DA medication at 
baseline (U = 281.0, p<0.005) than those who were consistently non-apathetic. Due to the 
sample size this was only completed using the self-rated apathy scores. 
 
Figure 5:  Flow-chart summarizing the re-classification of apathy in a cross-sectional sample of 106 HD patients 
with motor signs of disease ranging from mild to advanced  stages followed up on average for 18.7 (1.2) months 
from their first visit. Apathy was defined based upon published criteria [27]    
Table 2 Baseline demographic characteristics for all patients who completed the 
AES at both baseline and follow up. * indicates a significant difference 
compared to pre-manifest HD group at the p=0.05 level.  
 
  
 Pre-HD Early Moderate Late 
N 11 17 19 20 
Gender (m/f) 4:7 11:6 8:8 11:9 
Age 50.6 (15.1) 52.5 (14.2) 524 (7.7) 55.5 (13.5) 
CAG 42.0 (1.8) 42.8 (3.6) 41.8 (1.5) 44.9 (4.4) 
Disease duration -7.2 (6.8) 6.2 (7.2)* 10.3 (5.9)* 10.4 (4.1)* 
UHDRS 1.9 (1.8) 14.5 (7.2)* 23.6 (14.8)* 44.3 (10.6)* 
FA 24.4 (1.3) 23.9 (1.1) 20.1 (3.6)* 13.4 (4.9)* 
MMSE 28.2 (3.0) 26.9 (2.3) 26.4 (2.9) 22.1 (3.8)* 
BDI 7.0 (6.3) 5.6 (5.6) 13.1 (10.2) 10.6 (10.4) 
Phonemic fluency 38.6 (15.0) 28.9 (14.7) 25.2 (15.3) 26.7 (15.0)* 
Semantic fluency 20.8 (6.0) 14.6 (4.7) 13.3 (5.2)* 8.4 (3.4)* 
CANTAB PRM 17.5 (6.5) 16.2 (2.6) 16.3 (3.4) 13.8 (4.3) 
CANTAB SRM 11.3 (4.7) 13.3 (2.9) 14.1 (2.5) 12.1 (3.7) 
 
 
Abbreviations: BDI: Beck Depression Inventory, CAG: cytosine-adenine-guanine, CANTAB 
PRM: Cambridge Neuropsychological Test Automated Battery Pattern Recognition memory, 
CANTAB SRM: Cambridge Neuropsychological Test Automated Battery Spatial Recognition 
memory, FA: UHDRS Functional Assessment, UHDRS: Unified Huntington’s Disease Rating 
Scale  
 
Factors contributing to apathy score 
Principal component analysis (PCA) revealed that the same 11 questions emerged as explaining 
the majority of the variance in both the self-rated and companion rated AES (table 3), although 
the model created from the companion-rated scores also contained the additional item “someone 
has to tell them what to do each day”.    
 
 
Table 3 Items from the Apathy Evaluation Scale classified into components according to the results of the 
principal component analysis. Items written in bold* indicate questions present in the companion but not 
the self-rated model.  
Component 1 Component 2 Component 3 
Is interested in things Has an accurate understanding of their 
problems 
Puts little effort into anything 
Getting this started on own I important to 
them 
Has friends Is less concerned about problems than 
they should be 
Is interested in having new experiences Getting together with friends is 
important to them 
 
Is interested in learning new things   
Seeing a job through to the end is important   
Has initiative   
Has motivation   
Getting things done during the day is 
important 
  
Gets things done during a day   
Approaches life with intensity   
Spends time doing things that interest them   
Someone has to tell them what to do each 
day * 
  
Discussion  
In this study we used a well validated self-report questionnaire to compare; (1) two independent 
perspectives on apathy in a large cohort of HD patients and (2) to see how stabile any reported 
scores of apathy were over an 18 month follow up period. Importantly, the results of the current 
study confirmed that there is a good inter-rater reliability between the self-rated and companion 
rated AES. Coupled with this the results of the PCA demonstrated that both patients and 
companions rated apathy according to the same constructs within the scale. As such it is 
reasonable to conclude that patients are able to provide a useful evaluation of their level of 
apathy even in later stages of the disease, endorsing the use of self-rated apathy scales in an HD 
population. This has implications for the design of future therapeutic trials aimed at treating 
these features of apathy in HD. The freedom to use self-rating scales, in combination with or 
instead of companion rated scales means that companion-less patients need no longer be 
excluded from participating in such trials. Opening up recruitment in this way will help to reduce 
the bias and increase power of future studies in this clinical area.  
 
However, despite the overall agreement, it does appear that in early disease when cognitive 
performance is preserved, patients tend to rate their levels of apathy as higher than their 
companions whilst in later disease, when cognitive performance is worse, this relationship 
switches so that companions rate apathy as higher than the patients do. Others have reported a 
relationship between cognition and apathy in HD [15, 25] whereby patients with who perform 
worse on cognitive task are less accurate at rating their own apathy. The current study does not 
include an independent rating of the patient’s apathy therefore it is impossible to judge whether 
the patient or companion provides the more “accurate” rating but it is clear that the relationship 
between the two opinions does change as the disease advances. In light of this, it may still be 
prudent to consult both the patient and companion where possible.   
 
One advantage of the AES over other methods of rating apathy is the availability of published 
normative data and clinical cut-off values which can be used to classify an individual as 
apathetic or not. Using the published cut-off scores from the AES the prevalence of apathy in 
HD was estimated at between 26.9% and 50.6% depending upon whether the patient or 
companion reports are used. This is consistent with the previous literature which has cited a 
prevalence rate in the region of 50% [7] if you consider the companion data, with the lower cut 
off score (>39 compared to >41 for patient responses) being more accurate. It is possible that this 
is an over estimation of the true extent of apathy in the HD population given that patients and 
carers actually score apathy similarly. In which case it may be more appropriate to abandon the 
two tier approach and have one cut-off value that is applicable for both self-rated and 
companion-rated AES scores in HD.   
 
Beyond this the only area where self-rated and companion rated apathy scores yielded different 
results was in the relationship between apathy and cognition. Self-rated AES scores were 
significantly related to performance on the CANTAB SRM, whereas companion rated AES 
scores yielded differences on both verbal fluency tasks (phonemic and semantic) with non-
apathetic patients out-performing their apathetic counterparts. Baudic and colleagues [15] are the 
only group to date to have studied the impact of apathy on cognitive performance in HD in a 
systematic way using a comprehensive neuropsychological battery. They concluded that apathy 
has a detrimental effect on executive function, memory and cognitive efficiency. Although, 
unlike the results of this study they were unable to find an effect of apathy on either phonemic or 
semantic verbal fluency. These differences may be linked to the lower cut-off scores provided 
for the companion rated version of the AES compared to the self-rated cut-off scores, potentially 
leading to a relative overestimation of the prevalence of apathy in this population. This could go 
some way to explaining why the relationship between companion rated apathy and cognitive 
deficit presented in this study differs from that of self-rated apathy scores and from previous 
studies.     
 
Despite this, the majority of the findings of our current study are consistent with the existing 
literature. For example both self-rated and companion rated apathy increases with advancing 
disease with patients in the pre-manifest and early stages of HD reporting significantly lower 
AES scores than those at later stages of the illness [8]. However, apathy levels in moderate and 
late stage patients do not differ significantly from one another.  
 
As this effect is seen both in self-rated and companion rated scores it is unlikely to be an artifact 
of increasing cognitive impairment which occurs with advancing disease [30] making them 
unable to accurately evaluate their own apathy. One possible explanation is that the expectations 
of both patients and companions change as the disease progresses and therefore the reduced 
activity is attributed to the progressing motor impairment rather than to motivational factors. 
Additionally, there appears to be a degree of variability in the AES scores which cannot be 
explained in the context of disease severity but which may be indicative of different phenotypic 
subgroups of disease, with some patients being particularly susceptible to experience apathetic 
symptoms and others not. Further work in this area is needed to ascertain whether this is the 
case. 
 
In addition, the results of the current study provide additional evidence that apathy is distinct 
from depression. Whilst there is evidence of some overlap between apathy and depression scores 
in these patients, the level of apathy did not change as depressive symptoms increased supporting 
the independence of the two conditions. Furthermore, the degree of apathy did not change 
between patients who were or were not, using either antidepressant or dopamine blocking drugs 
but the numbers of patients in these groups were small and therefore the analysis was potentially 
underpowered.  
 
Finally and in contrast to the findings of other studies [8, 10] apathy appears to remain relatively 
constant over time in our study. This may reflect the slow rate of progression experienced by 
many patients with HD rather than a true “stability” especially given that companion AES scores 
did deteriorate significantly over the 18 month period. The studies which demonstrated an 
increase in apathetic symptoms over time studies their cohorts for 3 years [8, 10] whereas the 
one other study has failed to show a longitudinal change in apathy scores only had a follow-up 
period of 12 months [43]. A similar effect is seen in the cognitive domain where there is 
increasing evidence that extended periods of follow-up are needed to detect longitudinal change 
in performance [44, 45]. In addition, a retrospective power calculation demonstrated that the 
longitudinal study only had 35% power to detect change. Therefore, the results are insufficient to 
conclude that apathy is stable over time in HD.  
 
There are limitations with the current study that should be taken into consideration. Firstly, the 
majority of patients completed the cognitive tasks at the same time as the AES however, for 
some patients the time difference between completing the two was up to 1 year. Cognitive 
performance, specifically on the tasks used in this study have been shown to be stable over a 12 
month period and greater [46]. It is possible that the increased gap introduced variability into the 
data and therefore diluted the relationship between apathy and cognition in this study. In which 
caution should be expressed before concluding that apathy does not have a relationship with 
individual cognitive measures on the basis of the negative results presented here. Secondly, there 
was a high attrition rate in the study with 37.9% of patients not completing follow-up after 18 
months. Whilst this is unavoidable in studies of this nature it is important to acknowledge that 
this may have biased the data. At a group level patients who completed follow-up did not differ 
from the baseline group in terms of demographic information or clinical characteristics but it is 
still possible that there was a fundamental difference between the two groups. Finally, while the 
overall sample size is relatively large, when this is broken down in to smaller sub-groups based 
upon disease severity the number in each group becomes significantly smaller. Therefore, this 
work would need replicating in a larger cohort before this data can truly be used to support 
changes in clinical trial design.       
 
In conclusion, our new study demonstrates that the AES is a credible tool for measuring apathy 
in HD and may prove to be a valuable measure for use in future clinical trials. It is easy to 
administer, quick to complete and validated in multiple languages, although caution should be 
expressed when using the published cut-off scores as this may lead to an overestimation of 
apathetic symptoms if only the carers score is used. Furthermore, its utility may be limited by the 
apparent lack of change in scores in the short term although further work is needed to see if this 
varies as a function of disease stage. 
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